NetworkNewsBreaks – Syros Pharmaceuticals (NASDAQ: SYRS) Closes Underwritten Public Offering of $75.6 Million
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced that it has closed its underwritten public offering. The offering was comprised of 5,400,000 shares of common stock that were sold at $14 per share. In the announcement, the company noted that the public offering resulted in the gross proceeds of approximately $75.6 million, which Syros anticipates it will use to fund the development of its ongoing clinical and preclinical programs; the company may also use the monies for working capital and other general corporate purposes. Along with the closing, Syros noted…







